Table. 3 Treatment-Related Adverse Events

From: Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial

TRAE (n,%)

Preoperative treatment n = 30

ALL Grades

Grade 1

Grade 2

Grade 3

Any TRAEs

27(90%)

26(86.7%)

14(46.7%)

3(10%)

Leukopenia

15(50.0%)

2(6.7%)

11(36.7%)

2(6.7%)

Anemia

13(43.3%)

10(33.3%)

3(10.0%)

0

Thrombocytopenia

22(73.3%)

14(46.7%)

6(20%)

2(6.7%)

TSH increased

4(13.3%)

4(13.3%)

0

0

Hypothyroidism

1(3.3%)

1(3.3%)

0

0

ALT increased

1(3.3%)

1(3.3%)

0

0

AST increased

3(10%)

2(6.7%)

1(3.3%)

0

ALP increased

0

0

0

0

LDH increased

3(10%)

3(10%)

0

0

TBIL increased

0

0

0

0

GGT increased

0

0

0

0

INR increased

0

0

0

0

Gastrointestinal bleed

4(13.3%)

4(13.3%)

0

0

Rash

2(6.7%)

2(6.7%)

0

0

Fever

1(3.3%)

1(3.3%)

0

0

TRAE (n,%)

Adjuvant treatment n = 15

ALL Grades

Grade 1

Grade 2

Grade 3

Any TRAEs

9(60%)

9(60%)

5(33.3%)

1(6.7%)

Leukopenia

3(20.0%)

0

3(20.0%)

0

Anemia

3(20.0%)

2(13.3%)

1(6.7%)

0

Thrombocytopenia

3(20.0%)

3(20.0%)

0

0

TSH increased

2(13.3%)

2(13.3%)

0

0

Hypothyroidism

2(13.3%)

2(13.3%)

0

0

ALT increased

0

0

0

0

AST increased

1(6.7%)

0

1(6.7%)

0

ALP increased

1(6.7%)

0

0

1(6.7%)

LDH increased

1(6.7%)

1(6.7%)

0

0

TBIL increased

2(13.3%)

1(6.7%)

1(6.7%)

0

GGT increased

1(6.7%)

1(6.7%)

0

0

INR increased

2(13.3%)

2(13.3%)

0

0

Gastrointestinal bleed

0

0

0

0

Rash

0

0

0

0

Fever

0

0

0

0

  1. TRAEs treatment-related adverse events, TSH thyroid stimulating hormone, ALT alanine transaminase, AST aspartate amino transferase, ALP alkaline phosphatase, LDH lactate dehydrogenase, TBIL total bilirubin, GGT gamma-glutamyl transpeptidase, INR international normalized ratio.
Back to article page